Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
4.090
-0.570 (-12.23%)
At close: Nov 20, 2024, 4:00 PM
4.150
+0.060 (1.47%)
After-hours: Nov 20, 2024, 7:53 PM EST
Clene Revenue
Clene had revenue of $87.00K in the quarter ending September 30, 2024, a decrease of -19.44%. This brings the company's revenue in the last twelve months to $421.00K, down -41.36% year-over-year. In the year 2023, Clene had annual revenue of $654.00K with 38.27% growth.
Revenue (ttm)
$421.00K
Revenue Growth
-41.36%
P/S Ratio
62.75
Revenue / Employee
$4,953
Employees
85
Market Cap
32.64M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Farmer Bros. Co. | 344.27M |
Grove Collaborative Holdings | 213.78M |
Davis Commodities | 159.84M |
Natural Alternatives International | 112.98M |
Sow Good | 40.13M |
ATA Creativity Global | 35.75M |
Four Seasons Education | 17.45M |
United-Guardian | 12.31M |
CLNN News
- 7 weeks ago - Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data - GlobeNewsWire
- 2 months ago - Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. - GlobeNewsWire
- 3 months ago - Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 4 months ago - Clene to Present at the Emerging Growth Conference - GlobeNewsWire
- 4 months ago - Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS - GlobeNewsWire
- 4 months ago - Clene Announces 1-for-20 Reverse Stock Split - GlobeNewsWire